Standards for follow-up care of patients with breast cancer

被引:7
作者
Peppercorn, J [1 ]
Partridge, A [1 ]
Burstein, HJ [1 ]
Winer, EP [1 ]
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
breast cancer; therapy; follow-up;
D O I
10.1016/j.breast.2005.09.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the United States alone, over 200,000 women are diagnosed with invasive breast cancer each year, and another 50,000 are diagnosed with ductal carcinoma in situ. The vast majority of these women will survive for five or more years, and the majority will never experience a recurrence of their disease. Followup care is focused on the early identification of new primary cancer and locoregional recurrences. There is no clear evidence that early identification of distant metastases will. lead to an extension in survival, and for this reason routine imaging studies such as CT and PET scans are not recommended. Comprehensive care for breast cancer survivors should also address late complications of treatment and ongoing psychosocial problems that may have arisen as a result of a breast diagnosis and treatment. Although subspecialists often provide follow-up care for breast cancer survivors, randomized trials have demonstrated that generalists can provide such care. As the number of breast cancer survivors continues to increase, guidelines and programs to provide comprehensive, compassionate, and cost-effective follow-up care will become ever more important. (c) 2005 Published by Elsevier Ltd.
引用
收藏
页码:500 / 508
页数:9
相关论文
共 60 条
  • [1] ABE O, 1992, LANCET, V339, P71
  • [2] Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
    Arpino, G
    Bardou, VJ
    Clark, GM
    Elledge, RM
    [J]. BREAST CANCER RESEARCH, 2004, 6 (03): : R149 - R156
  • [3] Badger C, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003141.PUB2
  • [4] Bast RC, 1996, J CLIN ONCOL, V14, P2843
  • [5] BEDWINEK JM, 1981, CANCER, V47, P2232, DOI 10.1002/1097-0142(19810501)47:9<2232::AID-CNCR2820470921>3.0.CO
  • [6] 2-R
  • [7] Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
    Bendell, JC
    Domchek, SM
    Burstein, HJ
    Harris, L
    Younger, J
    Kuter, I
    Bunnell, C
    Rue, M
    Gelman, R
    Winer, E
    [J]. CANCER, 2003, 97 (12) : 2972 - 2977
  • [8] The Gothenburg Breast Screening Trial
    Bjurstam, N
    Björneld, L
    Warwick, J
    Sala, E
    Duffy, SW
    Nyström, L
    Walker, N
    Cahlin, E
    Eriksson, O
    Hafström, LO
    Lingaas, H
    Mattsson, J
    Persson, S
    Rudenstam, CM
    Salander, H
    Säve-Söderbergh, J
    Wahlin, T
    [J]. CANCER, 2003, 97 (10) : 2387 - 2396
  • [9] Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
    Braun, S
    Pantel, K
    Muller, P
    Janni, W
    Hepp, F
    Kentenich, CRM
    Gastroph, S
    Wischnik, A
    Dimpfl, T
    Kindermann, G
    Riethmuller, G
    Schlimok, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) : 525 - 533
  • [10] Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: A population-based study
    Chaplain, G
    Milan, C
    Sgro, C
    Carli, PM
    Bonithon-Kopp, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (15) : 2836 - 2842